This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (23)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Richard C. Pasternak, MD

JAMA. 2002;288:3042-3044.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid Lowering Trial (ALLHAT-LLT),¹ published in this issue of THE JOURNAL, is the second-largest lipid-lowering trial yet reported. This randomized trial, a subset of the larger ALLHAT hypertension study,² followed up 10 355 patients (49% women) who had hypertension and were 55 years or older for a mean of 4.8 years. Patients were randomly assigned to receive 40 mg of pravastatin (open label) vs "usual care" in 513 clinical centers, the majority of which were community-based. These centers were a subset of the 623 centers that treated patients for the larger (N = 33 357) ALLHAT hypertension study.² Despite a 28% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline in the pravastatin treatment group, the trial failed to show a benefit in either the primary outcome (all-cause mortality) or the key secondary outcome (combined nonfatal myocardial infarction and . . . [Full Text of this Article]

Author Affiliation: Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Lipid-Lowering Therapy and Risk of Coronary Events
Luca Mascitelli and Francesca Pezzetta
JAMA. 2003;289(16):2071.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
JAMA. 2002;288(23):2998-3007.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Statins for primary prevention in type 2 diabetes
DTB 2006;44:57-60.
ABSTRACT | FULL TEXT  

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor et al.
NEJM 2006;355:125-137.
ABSTRACT | FULL TEXT  

The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong
QJM 2005;98:599-614.
ABSTRACT | FULL TEXT  

Clinical Significance of Statin Pleiotropic Effects: Hypotheses Versus Evidence
Davidson
Circulation 2005;111:2280-2281.
FULL TEXT  

Primary Prevention of Coronary Heart Disease in the Elderly
Dornbrook-Lavender et al.
The Annals of Pharmacotherapy 2003;37:1654-1663.
ABSTRACT | FULL TEXT  

The Metabolic Syndrome: A Practical Guide to Origins and Treatment: Part II
Wilson and Grundy
Circulation 2003;108:1537-1540.
FULL TEXT  

Medical Management of Hyperlipidemia/Dyslipidemia
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2003;88:2445-2461.
FULL TEXT  

Lipid-Lowering Therapy and Risk of Coronary Events
Mascitelli and Pezzetta
JAMA 2003;289:2071-2071.
FULL TEXT  

Pravastatin Failed to Improve Outcomes in ALLHAT-LLT -- But Why?
Journal Watch Cardiology 2003;2003:2-2.
FULL TEXT